P otentially severe and persistent or recurrent mental disorders pose the major threat to the health, happiness, and productivity of young people as they emerge from childhood to approach the threshold of adult life. The World Economic Forum has recently revealed that mental disorders now equal cardiovascular diseases (CVDs) as the major threat among noncommunicable diseases to the gross domestic product of modern economies. 1 This is due largely to the timing in the life cycle of the onset of mental ill health, 2 with 75% of disorders emerging by age 25. Universal or primary prevention is the ultimate solution and must be actively researched and pursued where it works, though it is difficult to assemble solid evidence for this. 3 Where primary prevention is still out of reach (and the severe mood and psychotic disorders is one such domain), given we have a range of effective treatment strategies in psychiatry, there are 2 alternative pathways to actively follow.
First, we must substantially extend the coverage of current interventions so that the vast majority of people who can benefit from mental health care can gain access. Currently, even in wealthy developed nations, only a minority of people with a mental disorder and a consequent need for care actually receive it, and in developing countries access is minimal and quality of care poor. This is why we need to support the global campaign for mental health. 4, 5 Second, timing is crucial, and early intervention offers the best hope for disease modification and the reduction of the widespread psychological, social, and economic impacts of treatment delay and poor quality care. 6 This strategy is a cornerstone of mainstream health care, in cancer, diabetes, and CVD, yet early intervention or pre-emptive psychiatry 7, 8 has only recently been extended, deployed, and now widely endorsed within the mental health field. Even so, and somewhat surprisingly, a small yet diverse band of critics have not only questioned but also actively campaigned against early intervention concepts and reforms. Obviously such questioning is, to a significant extent, healthy and quite justifiable, being derived from a blend of genuine scientific conservatism, the late adopter phenomenon, and a valid fear of exposing patients to harmful stigma and overtreatment within traditional and narrow models of care, which can often do more harm than good and is more widespread than we care to acknowledge. However, the more extreme commentary on early intervention is evidence-poor and polemical, fueled by vested interests, apologists for the status quo of a narrow brand of traditional psychiatry, and, ironically, unreconstructed antipsychiatry. Nevertheless, we can take it as a positive that the tone and intensity of the debate indicates that real change and a genuine paradigm shift may be occurring. To succeed, it is crucial that early intervention remains strongly evidence-based.
The frontier for early intervention is the prodromal or subthreshold stage of illness when a need for care is demonstrable yet the diagnostically clear or pathognomonic features of a particular syndrome or illness have not yet revealed themselves. 9 The observation that such subthreshold or warning signs of future more severe illness, often lasting months or years, could be retrospectively identified was made more than 80 years ago by Sullivan 10 and countless clinicians since then. The latter have usually experienced a sense of frustration that had they come on the scene during this more subtle phase, which turned out to be a prodromal stage of illness, perhaps it would have been possible to avert much of the patients' suffering and functional disturbance that subsequently ensued. 10, 11 Careful research reconstructing the prodromal stage of psychotic illnesses [12] [13] [14] [15] enabled the creation of operational criteria that could be used prospectively to identify a group of patients who proved to be at incipient risk of transition to psychosis. 14, 15 This has spawned huge interest and a rich seam of descriptive, neurobiological, and intervention research in subthreshold psychosis during the past 15 years. The paradigm of the at-risk, ultra-high risk or clinical highrisk (mental) state, and the prodrome or the subthreshold stage has also been extended to the affective disorders. In this issue of The Canadian Journal of Psychiatry, 2 papers 16,17 look separately at prodromal or subthreshold stages of psychotic and bipolar disorders (BDs) in children and adolescents, with the traditional boundary line drawn at age 18. Dr Marta Hauser and Dr Christoph U Correll 16 have reviewed the potential value of this overall strategy for BD, while Dr Benno Graf Schimmelmann and colleagues 17 have focused upon at-risk symptoms of psychosis. 16 demonstrate that the diagnosis of BD is indeed preceded by earlier manifestations of mental ill health of a variable, fluctuating, and somewhat diffuse nature. One of the challenges for the prodromal concept is that these disturbances are usually of an intermittent nature and hence a distinction between distal prodromal, outpost syndromes, or premorbid features may often need to be made from proximal prodromes that may be of short-to-moderate duration immediately preceding a firstepisode mania, which secures the BD diagnosis. There is a parallel with schizophrenia, where full threshold positive psychotic symptoms are required for that diagnosis, with the preceding patterns then being recast in that light. There are challenges in defining a distinct prodromal signature for BD, which requires a full manic episode to manifest. One is that the premania prodrome is often episodic or discontinuous. Another challenge is that typically the first episode of clear-cut, full threshold mental illness is a depressive one. If the bar is lowered and hypomania becomes the defining feature, this problem is lessened but not abolished. Another unresolved and highly contentious issue, featured in this paper, is the real divergence between interpretation of clinical phenotypes in prepubertal children in the United States and the rest of the world. Hauser and Corell 16 seem to accept the US view that prepubertal BD is a real phenomenon, yet the clinical phenotype is expressed differently from cases of adolescent-or adult-onset BD. Consequently, they express surprise that the studies of Duffy et al 18, 19 find no evidence of this. However, non-US psychiatry is generally skeptical of the existence of prepubertal BD as a real entity. Further research is required to determine the boundaries between normal developmental experiences in younger children and mental ill health and disorder as well as how to subcategorize as precursor syndromes or variable phenotypic expression in childhood of underlying disorder, which continues to evolve in adult life.
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Similarly, Dr Schimmelmann and colleagues 17 focus on child-and adolescent-onset schizophrenia and psychosis and are hampered by the relatively small number of studies covering, or limited to, this age range in their analysis and recommendations. Prepubertal-onset schizophrenia and psychosis are rare, with most of the onsets occurring in late adolescence and young adulthood, as indeed is probably also the case with true BD. It remains to be seen if onset before the age of 18 really has any important differences with onsets after 18, a very arbitrary boundary based on legal and educational grounds rather than developmental or health principles. The authors 17 review the field of psychosis during adolescence and childhood, and their summary and clinical recommendations are cautious and well supported, as are those of Hauser and Correll. 16 However, when studying the onset stages of these potentially serious disorders, the artificial boundaries imposed by, first, the child-adolescent versus adult distinction and, second, the arbitrary diagnostic silos of schizophrenia and BDs, obscures our vision and make progress in early intervention difficult. Censoring the zone of interest with an upper limit of 18 years is a major problem because transition or conversion to psychosis or mania, the key outcome of interest, which defines what has gone before, peaks in the period between the ages of 16 and 25 for both syndromes. However, it is definitely worthwhile to commence the study of prodromes and subthreshold stages from late childhood and early adolescence. The onset or prodromal stage of the mood and psychotic disorders is predominantly during the period from puberty through to the mid-20s and must have a great deal to do with the interaction between genes, the developing brain, and the massive developmental and environmental stressors and risk factors operative during this stage of life. The clinical phenotype prior to the first psychotic, manic, and even severe depressive episode has some valence or specificity for the subsequent syndromal diagnosis but it does not seem to be strong enough yet for specific psychopharmacology. Even following first-episode psychosis or mania there is diagnostic flux over time. This is because our current descriptive diagnostic system was derived and has been reinforced within tertiary samples of older patients with a track record of persistent or recurrent illness and reasonable syndromal clarity and stability. It is found wanting when applied to the earlier stages of clinical disorder.
There are 2 ways forward for researchers of the prodromal or at-risk mental state. One is to seek to refine and perfect specific prodromal or risk criteria for the traditional diagnostic classes, employing enrichment strategies and trying to bolster clinical phenotypes with selected biomarkers. This assumes there are predetermined train lines to classical mental disorders that can be identified early in the journey. The other is to define more general, fluid, or pluripotential risk syndromes with a range of warning signs, or syndromes, that connote risk for several destination or exit disorders, with biomarkers of variable specificity for stage or syndrome. We are not yet clear as to which research approach will prove to have more validity, hence both may be pursued heuristically. However, Cuijpers 3 has explained why the latter approach may be more efficient regarding power to conduct predictive and intervention studies in a context where incidence rates are relatively low for individual disorders, such as BD and schizophrenia. His other suggestions for indicated prevention research include blending in additional or multiple risk factors, such as family history, childhood trauma, and unemployment, to increase the yield across the range of disorders.
I personally believe this latter pluripotential approach is more likely to bear fruit and suggest that a cross-diagnostic approach, which we call clinical staging, [20] [21] [22] will enable us to determine at what point specificity of treatment strategies (especially psychopharmacological interventions) can be characterized. Such an approach will also allow the riskbenefit principles outlined in both of these papers 16, 17 to be studied carefully, such that, in the early and less-specific stages, safer, psychosocial, and more generic interventions will be offered as a first-line treatment on a sound evidence base. A cross-diagnostic staging model also allows the neurobiological significance and diagnostic utility of biomarkers to be studied in a much clearer manner.
If we are able to engage young people with emerging mental ill health in stigma-free and holistic community settings, without the constraints of our flawed and siloed diagnostic systems, past and present, and our equally unhelpful and arbitrary age boundary of 18, then perhaps we will be able to make more rapid progress in this fascinating and critical frontier of psychiatry.
